Transplantation after high-dose chemotherapy prolongs survival in patients with multiple myeloma compared with standard therapy. It is unclear whether the optimal timing of transplantation is immediately after induction chemotherapy or whether stem cells may be cryopreserved for transplantation at subsequent progression or relapse. In this study, stem cells were collected within 6 months of diagnosis, followed by transplantation only at progression of myeloma. One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved. Eleven had transplants early in the disease after they demonstrated failure to respond to primary therapy. The remaining 107 were eligible for transplants when there was evidence of progressive disease. Of the 118 patients, 67 had transplants, nine died of progressive disease before transplantation, and 42 remain alive in plateau phase. The median survival of the group is 58.5 months; 67 are alive. Serum ␤ 2 -microglobulin, bone marrow labeling index (S phase), and hemoglobin level predicted overall survival (P Ͻ 0.006, P Ͻ 0.001, and P Ͻ 0.01, respectively). We conclude that early cryopreservation of blood stem cells followed by transplantation at progression is a feasible approach to therapy in patients with myeloma. The underlying biology of the disease has a greater impact on survival than the timing of transplantation. A prospective randomized trial is required to answer definitively the question of the optimal timing of blood cell transplantation. Keywords: multiple myeloma; blood cell transplantation; stem cell; myeloma prognosis Multiple myeloma is a malignancy in which chemotherapy dose escalation is an effective strategy capable of high kill of tumor cells, including drug-resistant cells.
vests from the majority of myeloma patients contain myeloma cells. 3 Patients whose stem cell collections contain plasma cells have a shorter duration of response. 4 Attempts to decrease the number of harvested myeloma cells include in vitro purging with cytotoxic agents, 5 monoclonal antibody purging, 6 and positive selection of CD34-positive cells. [7] [8] [9] Attempts to differentially mobilize stem cells without purging have also been reported. 10 In spite of intensive research in the area of transplantation for myeloma, many questions remain unanswered, including the optimal conditioning regimen 11 and the role of post-transplant interferon. 12 The optimal timing of transplant also remains unknown and is the current subject of a randomized intergroup study comparing early with late transplantation. We report our experience with early harvest and late transplantation as a strategy to maximize survival in patients who have multiple myeloma.
Materials and Methods

Patient Population
The patients included in this study had multiple myeloma and underwent blood stem cell collection and transplantation between May 1989 and January 1997. All patients gave informed written consent. Consent was in accordance with the Declaration of Helsinki. The consent form was approved by the Institutional Review Board of the Mayo Foundation. All patients were followed until 1 October 1997, and none were lost to follow-up. All patients were placed on vincristine, adriamycin (doxorubicin), and dexamethasone (VAD) infusional chemotherapy for a planned four cycles. 13 Fifteen of the patients had prior exposure to melphalan-based chemotherapy initiated at their home institution before being seen at the Mayo Clinic. The duration of prior therapy was 0.1 to 7 months (median, 2.5 months). Three patients were refractory, two had transplants and relapsed off therapy, and 10 had transplants and relapsed on therapy. Stem cells were collected after the completion of VAD chemotherapy. The first 14 patients had stem cells collected in the steady state without mobilization. Forty-six patients received granulocyte colony-stimulating factor (G-CSF) priming (5 g/kg) subcutaneously daily until the completion of peripheral blood stem cell collection with apheresis beginning on the fifth day after the initiation of G-CSF.
14, 15 The subsequent 58 patients received cyclo-phosphamide intravenously (1.5 g/m 2 ) daily for 2 days, followed by G-CSF (5 g/kg) subcutaneously daily beginning on day 3 and continued until collection was completed. 16 Stem cell apheresis began when the total white cell count recovered to Ͼ500/l.
An average of 14 l of blood (4-h leukapheresis) was processed per procedure. The target progenitor cell number was 8 ϫ 10 8 mononuclear cells/kg. This goal was achieved in 113 patients. All but one patient attained Ͼ6 ϫ 10 8 mononuclear cells/kg. Conditioning was based on whether the patient was a candidate for total body irradiation, given 2 Gy twice daily on days Ϫ3, Ϫ2 and Ϫ1. Patients with extensive prior irradiation to bony sites were evaluated by a radiation oncologist to determine suitability for radiation. Patients who were not candidates for total body irradiation received melphalan (200 mg/m 2 ), with the exception of three patients during a period when melphalan was not commercially available and cyclophosphamide was substituted.
Timing of transplant
At the completion of the stem cell collection, patients were assessed for response. Patients who showed no evidence of an objective response, defined as a 50% reduction in the serum and urine M protein, were considered primary treatment failures to VAD and went directly to transplantation. 17, 18 All remaining patients were placed on vincristine, BCNU, melphalan, cyclophosphamide, and prednisone (VBMCP) chemotherapy in standard doses with a planned schedule of 12 cycles. Patients who showed evidence of progressive disease at any time during or after the completion of the VBMCP chemotherapy went directly to transplantation. Interferon was not administered routinely as part of this protocol.
Statistical analysis
No patients were excluded from analysis. Survival analysis was performed using the Kaplan-Meier method. Multivariate analysis was performed using the proportional-hazards model (Cox). All P values were calculated by log-rank (Mantel-Cox) test.
Results
The characteristics of the 118 patients who underwent stem cell collection are given in Table 1 . All patients had overt and symptomatic disease; asymptomatic patients were excluded from participation. Eighty-four percent of patients had radiographically demonstrable myeloma bone disease. Nearly one-third had a hemoglobin level р10 g/dl at presentation. The biochemical characteristics of these patients are given in Table 2 . Nearly 60% of the patients had an elevated ␤ 2 -microglobulin concentration, suggesting a high tumor burden, and 35% had evidence of kinetically active disease indicated by a labeling index Ͼ0.8% by the slidebased method of Greipp. 19 The median percentage of bone marrow plasma cells at diagnosis was 50%. An insufficient CTX ϭ cyclophosphamide; G-CSF ϭ granulocyte colony-stimulating factor; TBI ϭ total body irradiation.
number of patients had C-reactive protein measurements for inclusion in the statistical model. 20 Of the 118 patients, 21 were recognized as having an antecedent plasma cell dyscrasia before overt multiple myeloma developed. Survival calculations were made from the date chemotherapy began after the transformation to overt symptomatic myeloma. All five patients with a solitary plasmacytoma had received local radiotherapy previously. Of the 118 patients, 67 have had transplants to date. Eleven patients had transplants immediately after stem cell cryopreservation as primary treatment failures. One hundred and seven patients went on to VBMCP chemotherapy, and 56 had transplants because of progression on treatment or relapse after treatment was discontinued ( Table  2 ). All but six of the patients responded to transplantation with a median freedom from progression of 9.3 months. Nine patients died of progressive disease without having had transplants. Six of these patients did not have transplants because of subsequent insurance denial, and three patients died with explosive relapses before transplantation could be initiated. Forty-two patients remain alive in a stable plateau with stem cells cryopreserved. Overall, 20 patients did not undergo late transplantation. Figure 1 represents the actuarial survival curve for all 118 patients who had stem cells collected. The median survival of all patients was 58.5 months. Of the 67 patients who have had transplants, 42 have died: five had transplantrelated mortality and 37 died of progressive disease. Of the 11 primary refractory patients, five remain alive. Of the 56 patients transplanted after relapse, 20 survive. The median survival of the 67 patients measured from day 0 of transplant was 17.2 months. The median survival seen in this study post-transplant suggests that maintaining the remission is more difficult. Figure 2 gives the actuarial time from diagnosis to transplant. A median time of 38 months was observed before progression of disease led to transplantation. An analysis of labeling index, age, percent marrow plasma cells, albumin, levels of serum and urine M protein, ␤ 2 -microglobulin, calcium, creatinine, and hemoglobin was performed, comparing patients in the three groups: refractory, relapse off therapy, and relapse on therapy. No differences were found (Kruskal-Wallis).
Univariate analysis of factors predicting survival was performed (Table 3 ). All factors were measured at initial diagnosis. Factors found not to be significant include sex, serum and urine M protein size, type of heavy chain, and percent bone marrow plasma cells. A subsequent multivariate analysis was performed using factors shown to be significant in the univariate model, and only three were predictive of overall survival from diagnosis ( Table 4 ). The serum ␤ 2 -microglobulin, the slide-based labeling index, and the hemoglobin level were significant factors in this model. Figures 3 and 4 demonstrate the impact of ␤ 2 -microglobulin and labeling index on overall survival in this cohort of patients.
Discussion
It has been demonstrated that transplantation can result in superior survival for patients with multiple myeloma compared with standard chemotherapy. 2 However, the treatment is not curative. Failure to cure myeloma may be because of the reinfusion of tumor cells 21 or because current con- Table 4 Multivariate analysis (Cox) of factors predicting survival in the univariate model ditioning regimens are incapable of eradicating all residual myeloma. 22 Since transplantation is not curative, a legitimate question is whether the optimal timing of transplant is early in the course of disease or late. The question of early or late transplantation is being addressed as part of the ongoing intergroup trial in the United States and by a randomized trial by French investigators. The French have found no survival advantage of early transplantation. 23 Early transplantation has the theoretical advantage of introducing high-dose therapy before the induction of tumor resistance and at a time of low tumor burden. High-dose therapy could theoretically be more beneficial to patients with chemotherapy-sensitive disease when applied early in the disease course. 24 Late transplantation has the advantage of deferring transplant-related morbidity and mortality to late in the course of the disease, applying high-dose therapy when the tumor burden is high and the patient will derive symptomatic clinical benefit. The French investigators have suggested that quality of life may be reduced in patients undergoing late transplantation. 25 A considerable amount of patient selection occurs when patients with multiple myeloma undergo transplantation. Because transplantation in myeloma is often limited to larger medical centers, there is selection bias for patients able to travel to these centers. In a recently published report from the European Group for Blood and Marrow Transplantation, 26 the median time from diagnosis of myeloma to autologous stem cell transplant was 15 months. A second study reporting on 40 patients gave a median time from diagnosis to transplant of 18.6 months. 27 Clearly, some patients who go on to transplant have been selected by their initial ability to survive to the point of transplant, making this an inherently more favorable group.
Delayed transplantation allows for deferral of the treatment-related mortality associated with high-dose chemotherapy. In the multicenter European transplant group, treatment-related mortality for the years 1992-1994 was 7%. 26 Previous reports have indicated limited benefit using highdose chemotherapy in heavily pretreated patients. 28 Vesole et al 29 reported post-transplantation survival of 2 years compared with our post-transplantation survival of 17 months, consistent with the possibility that transplantation later in the disease course involves multidrug-resistant cells. However, in prior studies, stem cells were mobilized and harvested after extensive prior chemotherapy. That approach is known to result in significantly delayed hematopoietic recovery post-transplantation 30 and could conceivably result in the collection of therapy-resistant tumor cells. Our study differs in that stem cells were mobilized early in the disease course to ensure prompt subsequent engraftment. Treatment-related mortality in our protocol was comparable (7%) to that from centers where transplantation was undertaken earlier in the disease course. The mortality we observed may be greater than at large centers where early transplantation may be associated with a mortality as low as 1%. 29 Our reported overall survival of 58.5 months appears quite similar to other series reported in the literature in which transplantation was used as up-front intensification. This study was not designed to answer this question and results of randomized studies are required to reach any definite conclusions. The group from the University of Arkansas has reported overall survivals of 4 to 5 years posttransplant 31 and has reported median survivals exceeding 5. years, in a selected group that had low concentrations of ␤ 2 -microglobulin and C-reactive protein. 29 There are several reports emphasizing the higher complete response rate in patients treated with high-dose therapy compared with those who are treated with more traditional chemotherapy. This has been used as a justification for ever-increasing intensity of therapy on the assumption that higher complete response rates will result in improved overall survival. Nonetheless, even patients who achieve a complete response ultimately relapse; in nonrandomized studies, it is difficult to determine whether achievement of complete response reflects superior therapy or whether those patients who achieve a complete response have inherently more sensitive tumors and are ultimately destined to do well because of favorable biology and sensitive disease rather than treatment intensity. Attal et al 32 reported a 43% complete response rate and noted that the best predictive factor for survival was a low pretreatment concentration of ␤ 2 -microglobulin. The European Group for Bone Marrow Transplantation found that age younger than 45 years and low serum ␤ 2 -microglobulin levels predicted improved survival after transplantation. 33 However, this same group is known to have an improved survival with standard melphalan chemotherapy. 34 One cannot overemphasize the importance of tumor biology in predicting the outcome of myeloma transplant studies. Virtually all published studies indicate that high ␤ 2 -microglobulin concentration, high labeling index, and low hemoglobin levels are adverse prognostic factors in highdose therapy and stem cell transplantation. 35 These are the same prognostic factors that predict a poor outcome with conventional therapy. 36 Patients with a high ␤ 2 -microglobulin value and high labeling index may be candidates for earlier transplantation. One may interpret this as indicating that patients who need transplant the most benefit the least from the procedure and that biologic variables dictate outcome more than the specifics of treatment or its timing. Using early transplant, the Royal Marsden group reported a 63% survival at 54 months 37 compared with our current study in which survival at 54 months was 56% (Figure 1 ). Raje et al 38 reported a median overall survival of 4.4 years, which does not appear different from our reported results using delayed transplantation.
Transplantation is a useful up-front technique in patients who are refractory to primary therapy. A report from the group in Seattle indicated a survival probability of 43% at 3 years in a group in which two-thirds of the patients had resistant disease. 39 Likewise, the MD Anderson group reported that high-dose melphalan can overcome resistance to standard chemotherapy in selected patients with advanced myeloma. 40 Alexanian et al 41 found that refractory patients who received transplants early had median survivals of 83 months. Jagannath et al 42 reported a Ͼ75% cytoreduction in all 21 patients with refractory myeloma. This supports the use of transplantation in primary refractory disease. High-dose melphalan resulted in further cytoreduction in only 56% of 34 patients who were already in remission after VAD, indicating that there is less opportunity for further cytoreduction in patients who have achieved a prior response to chemotherapy.
The Nordic Bone Marrow Transplantation Group recently reported on salvage chemotherapy following relapse after autologous stem cell transplantation in myeloma, reporting a 50% complete response rate after transplantation. 43 This compares with our 30% complete response rate in patients transplanted after failing at least one line of chemotherapy. Our patients' median survival of 17.2 months after transplantation is clearly inferior to the anticipated survival in patients who receive transplants early in the disease course. However, our patients' overall survival with planned late transplantation does not appear different from a large number of studies reported in the literature, suggesting that late transplantation after early mobilization of stem cells is a reasonable alternative that avoids early transplant-related mortality for patients, yet allows them the option for high-dose chemotherapy later using stem cells that have not been exposed to alkylating agents. 44 High-dose chemotherapy clearly can overcome resistant disease and should contribute to improved survival.
Our results lead us to conclude that early transplantation is appropriate for patients with refractory disease, but that the timing of autotransplantation in patients with chemotherapy-sensitive disease may not have a substantive impact on overall survival. Overall outcome is determined primarily by the biologic features of a patient's myeloma rather than the timing of high-dose therapy. Continued innovation will be required to improve the outcome in these patients. 45, 46 
